Skip to main content

Antibody-based IL-7R targeted therapies

Project description

A novel immunotherapy for acute lymphoblastic leukaemia may be widely applicable

Interleukin 7 (IL-7) and its receptor (IL-7R) are essential for lymphoid development. Their absence leads to severe immunodeficiency. In contrast, excessive IL-7/IL-7R-mediated signalling can lead to the development of acute lymphoblastic leukaemia (ALL), and accelerate its progression and resistance to chemotherapy. Despite tremendous progress in ALL treatment, long-term remission statistics demonstrate an important need to develop more effective therapeutic strategies. IL7RsignaTHER is investigating IL-7/IL-7R-mediated signalling pathways in leukaemic cells as well as the expression of IL-7R on these cells. A better understanding of this signalling pathway could point the way to improved antibody-based biopharmaceuticals. In addition to improving ALL treatment efficacy and reducing detrimental side-effects, they may help treat many other IL-7-linked diseases and conditions.

Host institution

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Net EU contribution
€ 150 000,00
Address
Avenida Prof Egas Moniz
1649 028 Lisboa
Portugal

See on map

Region
Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa
Activity type
Research Organisations
Other funding
No data

Beneficiaries (1)

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Portugal
Net EU contribution
€ 150 000,00
Address
Avenida Prof Egas Moniz
1649 028 Lisboa

See on map

Region
Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa
Activity type
Research Organisations
Other funding
No data